Onexton costs between $700 and $865 for a single 50-gram tube at most U.S. pharmacies, making it one of the pricier acne treatments on the market. The short answer: patent protection keeps generic competitors off the shelves, and the manufacturer has little incentive to lower the price while that protection lasts.
What Onexton Actually Is
Onexton is a prescription gel that combines two well-known acne-fighting ingredients: clindamycin (an antibiotic) and benzoyl peroxide (which kills bacteria and unclogs pores). These two ingredients have been available in combination gels for years under names like BenzaClin and Duac. What makes Onexton different is its specific concentration: 1.2% clindamycin with 3.75% benzoyl peroxide. That benzoyl peroxide level is lower than most older combination products, which typically use 5% or higher. The idea is that a lower concentration may cause less dryness and irritation while still clearing acne effectively.
In the clinical trial used for FDA approval, patients using Onexton saw a 60% reduction in inflammatory lesions (red, swollen pimples) and a 52% reduction in non-inflammatory lesions (blackheads and whiteheads) after 12 weeks. Patients using a plain vehicle gel with no active ingredients saw roughly half those improvements. Those are solid results, but they’re in the same ballpark as other clindamycin/benzoyl peroxide combinations that cost far less.
Patent Protection Through 2029
The biggest driver of Onexton’s price is its patent status. According to the FDA’s Orange Book, the last qualifying patent on Onexton doesn’t expire until August 5, 2029. Until then, no other manufacturer can sell a true generic version of the exact same 1.2%/3.75% formulation. This gives the manufacturer, Bausch Health (through its Ortho Dermatologics division), exclusive control over pricing.
This is common across the pharmaceutical industry. Brand-name drugs carry high prices during their patent window because the manufacturer needs to recoup development costs and, frankly, because they can. Once that window closes and generics enter the market, prices typically drop by 80% or more. For now, Onexton sits in that protected window where competition simply doesn’t exist for this specific product.
Insurance Often Won’t Cover It
Even with insurance, you may hit a wall. Many insurers place Onexton behind a prior authorization requirement, meaning your doctor has to submit extra paperwork proving you need it. Some plans, like Health Net, explicitly require that you’ve already tried and failed on a cheaper generic clindamycin/benzoyl peroxide product before they’ll approve coverage for Onexton. Others don’t cover it at all.
This creates a frustrating loop: the drug is expensive, insurance makes it hard to get, and patients end up staring at a cash price north of $700. The result is that many people searching “why is Onexton so expensive” are likely seeing that price for the first time at the pharmacy counter after their doctor wrote the prescription.
The Manufacturer’s Savings Program
Bausch Health does offer a savings card through its Ortho Dermatologics Access Program. If your commercial insurance covers Onexton, the card drops your copay to $0 for up to 6 fills. If your insurance doesn’t cover it or you’re paying cash, the price drops to $90 per fill for up to 2 fills. After those initial fills run out, you’re back to paying the full uninsured price.
There are significant restrictions. The savings card isn’t available to anyone on Medicare or Medicaid, anyone 65 or older without commercial insurance, or residents of Massachusetts, Minnesota, or (for products with a generic equivalent) California. It also can’t be used at government-subsidized clinics. So while $90 sounds dramatically better than $700, it’s a temporary discount with a narrow eligibility window.
Cheaper Alternatives That Work Similarly
Here’s the practical question most readers actually need answered: do you need Onexton specifically, or will something else work just as well for less money?
Several other combination gels pair clindamycin with benzoyl peroxide. Brands like BenzaClin and Duac have been around longer, and generic versions of those formulations are available. The main difference is the benzoyl peroxide concentration. Onexton uses 3.75%, while most generics use 5%. If your skin tolerates the slightly higher concentration without excessive dryness or peeling, a generic clindamycin/benzoyl peroxide gel delivers the same two active ingredients at a fraction of the cost.
You can also use the two ingredients separately. Over-the-counter benzoyl peroxide washes and gels are widely available for under $15, and generic prescription clindamycin gel or lotion typically costs $20 to $60 with a coupon. Using both isn’t quite as convenient as a single pump bottle, but the combined cost is a tiny fraction of Onexton’s price tag. If your dermatologist prescribed Onexton, it’s worth asking whether a generic combination or separate products would be a reasonable substitute.
Why the Price Stays High
Onexton’s price reflects a familiar pattern in U.S. dermatology. Manufacturers develop a slightly modified version of existing ingredients, patent the new formulation, and price it as a premium product. The lower benzoyl peroxide concentration in Onexton is a genuine tweak that may benefit people with sensitive skin, but it’s not a breakthrough new molecule. It’s a new ratio of two ingredients that have been treating acne for decades.
Bausch Health also operates a direct cash-pay program called Dermatology.com, which sells some of its branded dermatology products at set prices to bypass insurance complications. The program is designed to offer “predictable prices” without prior authorization headaches, though the prices still reflect brand-name positioning rather than generic-level affordability.
Until the patent expires in 2029, the pricing dynamics won’t fundamentally change. If you’re paying out of pocket, the manufacturer savings card (if you qualify) or switching to a generic alternative are the two most practical ways to avoid the full sticker price.